Table 3.
Evaluation of the effectiveness of the intervention on the variables of interest.
| Response Variables | Control Group n = 22 (42.31%) | Experimental Group n = 30 (57.69%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Difference (Post-Pre) |
95% CI | p-Value | Pre | Post | Difference (Post-Pre) |
95% CI | p-Value | |||
| A | B | A | B | |||||||||
| WOMAC | ||||||||||||
| Pain | 7.82 (1.82) | 5.18 (2.67) | −2.64 (1.81) | (−3.44, −1.83) | <0.00001 | 0.00008 | 8.83 (3.65) | 4.67 (2.9) | −4.17 (3.31) | (−5.4, −2.93) | <0.00001 | <0.00001 |
| Stiffness | 3.77 (1.11) | 2.5 (1.22) | −1.27 (1.35) | (−1.87, −0.67) | 0.0002 | 0.001 | 2.9 (1.32) | 2.3 (1.24) | −0.6 (1.16) | (−1.03, −0.17) | 0.008 | 0.009 |
| Functional capacity | 27.32 (7.21) | 19.95 (7.52) | −7.36 (5.55) | (−9.82, −4.9) | <0.00001 | 0.0002 | 27.93 (9.49) | 17.13 (8.61) | −10.8 (7.1) | (−13.45, −8.15) | <0.00001 | <0.00001 |
| Lattinen | ||||||||||||
| General | 12.09 (3.28) | 10.5 (3.05) | −1.59 (1.74) | (−2.36, −0.82) | 0.0003 | 0.002 | 12.03 (3.38) | 9.9 (3.17) | −2.13 (2.49) | (−3.06, −1.2) | 0.00006 | 0.00008 |
| Intensity | 2.59 (0.96) | 1.86 (0.89) | −0.73 (0.83) | (−1.09, −0.36) | 0.0005 | 0.002 | 2.43 (0.86) | 1.93 (0.87) | −0.5 (0.9) | (−0.84, −0.16) | 0.005 | 0.007 |
| Frequency | 2.77 (0.92) | 2.41 (1.18) | −0.36 (0.85) | (−0.74, 0.01) | 0.06 | 0.06 | 2.87 (0.9) | 2.1 (0.84) | −0.77 (0.9) | (−1.1, −0.43) | 0.00006 | 0.0004 |
| Analgesics | 1.91 (0.81) | 1.86 (0.71) | −0.05 (0.58) | (−0.3, 0.21) | 0.71 | 0.78 | 2.27 (0.83) | 1.93 (0.83) | −0.33 (0.66) | (−0.58, −0.09) | 0.01 | 0.02 |
| lncapacity | 2 (0.62) | 1.82 (0.5) | −0.18 (0.5) | (−0.4, 0.04) | 0.1 | 0.13 | 1.9 (0.66) | 1.63 (0.61) | −0.27 (0.52) | (−0.46, −0.07) | 0.009 | 0.01 |
| Pain induced insomnia | 2.68 (1.25) | 2.5 (1.41) | −0.18 (0.59) | (−0.44, 0.08) | 0.16 | 0.2 | 2.3 (1.34) | 2.27 (1.44) | −0.03 (1.45) | (−0.57, 0.51) | 0.9 | 0.75 |
| EuroQoL | 9.5 (1.85) | 8.5 (1.9) | −1 (1.07) | (−1.47, −0.53) | 0.0003 | 0.0008 | 9.07 (1.55) | 8.03 (1.61) | −1.03 (1.56) | (−1.62, −0.45) | 0.001 | 0.002 |
| HAQ | 1.38 (0.47) | 0.97 (0.49) | −0.4 (0.23) | (−0.5, −0.3) | <0.00001 | 0.00007 | 1.21 (0.54) | 0.85 (0.47) | −0.35 (0.34) | (−0.48, −0.23) | <0.00001 | 0.0001 |
| Yesavage | 1.55 (1.3) | 1.27 (1.2) | −0.27 (0.94) | (−0.69, 0.14) | 0.19 | 0.22 | 1.7 (1.8) | 1.43 (1.65) | −0.27 (0.69) | (−0.52, −0.01) | 0.04 | 0.049 |
| Reduction VAS (Pre—Post) |
0.24 (0.90) | 0.06 (0.74) | −0.17 (1.06) | (−0.79, 0.44) | 0.56 | 0.53 | 1.26 (1.63) | 0.74 (1.20) | −0.52 (1.53) | (−1.15, 0.11) | 0.11 | 0.09 |
Effect observed in CG and EG calculated as the difference in the mean value observed at the end of the trial (post) with respect to the corresponding value at baseline (pre-intervention). Average values observed in each group pre- and post-intervention and the mean of the effect (with the corresponding standard deviation) are shown, with the corresponding 95% CI, assessed using a Student T test (A) or a Wilcoxon (B) test for paired data. WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; HAQ: Health Assessment Questionnaire; VAS: Visual Analog Scale.